In this study, we demonstrate MYC and BRF2 alterations co-occur in breast invasive carcinoma, p = 0.008 (Fig. 8a-c), as well as patients aged 46–50 with metastatic breast cancer, p = 0.053 (Fig. 8H). Here, BRF2 is linked to invasive breast carcinoma.